Abstract: An approach for indicating viral safety of enclosed spaces. Absolute humidity (AH) values AHV (AHV1, AHV2, . . . , AHVn) are received from a set of sensors S (S1, S2, . . . , Sn) placed at locations L (L1, L2, . . . , Ln). The received absolute humidity values AHV (AHV1, AHV2, . . . , AHVi, AHVn) are compared to a viral safety safe value to determine a viral safety assessment of one of safe and not safe. An action is performed when the viral safety assessment is not safe.

Abstract: An approach is disclosed for activating cell-mediated herd immunity (CMHI) in a group of people. A scalable infrastructure is provided with one or more compliance protocol targets to facilitate activation of at least one of the four types of individual cell-mediated immunity (CMI): absolute humidity CMI, vitamin D CMI, gut microbiome CMI, and antiviral priming CMI, in the group of people. The activation is for at least one of: absolute humidity CMHI, vitamin D CMHI, gut microbiome CMHI, and antiviral priming CMHI in the group of people. The CMHI is achieved in the group of people when the compliance protocol targets are achieved.

Abstract: An approach is disclosed for applying a preventative treatment to a person to rapidly activate individual cell-mediated immunity (CMI). A first consumable product is manufactured in a form of an ingestible cream sealed in an oxygen proof sachet wherein the consumable product includes non-pharmaceutical phytochemicals with intrinsic biomolecular properties that inhibit enzymes critical to viral replication and moderately high daily dosages of vitamin D. A second consumable product is manufactured including prebiotic, probiotic, micronutrients, and select non-pharmaceutical nutraceuticals. The first consumable product is combined with the second consumable product as a single daily dose. The single daily dose is marketed for the rapid activation of CMI of the person.